Advanced Solid Tumor clinical trials

Explore recruiting advanced solid tumor clinical trials.

Recruiting advanced solid tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Solid Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations

Germany, Italy, Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants with Solid Cancers Treated with Cemiplimab

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

Spain, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors

Spain, Portugal

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

France, Belgium, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Solid Tumor trials by city

Advanced Solid Tumor in Toronto Advanced Solid Tumor in Vancouver Advanced Solid Tumor in Montreal Advanced Solid Tumor in Calgary Advanced Solid Tumor in Edmonton Advanced Solid Tumor in Ottawa Advanced Solid Tumor in Winnipeg Advanced Solid Tumor in Quebec City Advanced Solid Tumor in Hamilton Advanced Solid Tumor in Kitchener Advanced Solid Tumor in London Advanced Solid Tumor in Halifax Advanced Solid Tumor in New York Advanced Solid Tumor in Los Angeles Advanced Solid Tumor in Chicago Advanced Solid Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease